Amid a heated takeover fight with Valeant, Allergan says it's got a mystery suitor. But according to The Wall Street Journal 's sources, it's not all that mysterious.
Looking to build an oncology powerhouse, AstraZeneca has scooped up the diagnostics player Definiens with a down payment of $150 million while executing another drug development partnership with J&J and Pharmacyclics to add to its growing portfolio of immuno-oncology deals
Another hurdle toward the long-anticipated closure of Covidien's $43 billion merger with Medtronic was crossed today. Covidien announced that it is selling its clinical-stage Stellarex drug-coated angioplasty balloon for peripheral artery disease to Spectranetics for $30 million.
Diagnostics giant LabCorp is buying its way into the upper ranks of the CRO business, signing a deal to pay $5.6 billion for Covance and create an end-to-end testing conglomerate.
Shares of IDEXX Laboratories rose nearly 5% to $141.67 last week after reporting third-quarter net income that handily beat analyst estimates and announcing the acquisition of Netherlands-based Animana, which makes software for veterinary practices.
A string of acquisitions has revenue rolling at Charles River Laboratories, and the CRO has inked another M&A deal it hopes will pay off with a larger market share.
No Shire? No problem for AbbVie. At least, for now.
The long-anticipated acquisition of Biomet by Zimmer Holdings is almost slated to close. The resulting entity will be known as Zimmer Biomet; it has already unveiled a planned new organizational structure and an executive team that draws heavily on the soon-to-be-incorporated Biomet. The deal to create this musculoskeletal giant is expected to close during the first quarter of 2015.
Deal-hungry Perrigo is looking for more seats at the over-the-counter table, and the drugmaker may soon get its wish. The company has entered exclusive talks to acquire Belgian OTC maker Omega Pharma, inching past big-name competitors like Sanofi, Actavis and Boehringer Ingelheim.
Moody's Investors Service and Standard & Poor's Ratings Services are expected to downgrade Medtronic's debt due to the company's impending merger with Covidien. Under the new rules imposed by the Treasury Department, Medtronic will have to borrow $16.3 billion to fund the $43 billion transaction, as opposed to the initially planned $2.8 billion.